Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Nefeli Zacharopoulou, Galatea Kallergi, Saad Alkahtani, Anna Tsapara, Saud Alarifi, Evi Schmid, Basma Sukkar, Sotirios Kampranis, Florian Lang & Christos Stournaras. (2020) The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility. Cancer Biology & Therapy 21:6, pages 533-540.
Read now
Read now
Peng-Cheng Lv, Ai-Qin Jiang, Wei-Ming Zhang & Hai-Liang Zhu. (2018) FAK inhibitors in Cancer, a patent review. Expert Opinion on Therapeutic Patents 28:2, pages 139-145.
Read now
Read now
Panagiotis Kratimenos, Ioannis Koutroulis, Dante Marconi, Vasiliki Syriopoulou, Maria Delivoria-Papadopoulos, George P Chrousos & Stamatios Theocharis. (2014) Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase–Src–Paxillin system. Expert Opinion on Therapeutic Targets 18:12, pages 1395-1406.
Read now
Read now
Ekambaram Shanthi, Mudeenahally H Krishna, Gubbi M Arunesh, K Venkateswara Reddy, Jegatheesan Sooriya Kumar & Vellarkad N Viswanadhan. (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opinion on Therapeutic Patents 24:10, pages 1077-1100.
Read now
Read now
Elena Kurenova, Deniz Ucar, Jianqun Liao, Michael Yemma, Priyanka Gogate, Wiam Bshara, Ulas Sunar, Mukund Seshadri, Steven N Hochwald & William G Cance. (2014) A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle 13:16, pages 2542-2553.
Read now
Read now
Rebecca L Stone, Keith A Baggerly, Guillermo N Armaiz-Pena, Yu Kang, Angela M Sanguino, Duangmani Thanapprapasr, Heather J Dalton, Justin Bottsford-Miller, Behrouz Zand, Rehan Akbani, Lixia Diao, Alpa M Nick, Koen DeGeest, Gabriel Lopez-Berestein, Robert L Coleman, Susan Lutgendorf & Anil K Sood. (2014) Focal adhesion kinase. Cancer Biology & Therapy 15:7, pages 919-929.
Read now
Read now
Giovanni Germano, Alberto Mantovani & Paola Allavena. (2011) Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine 43:8, pages 581-593.
Read now
Read now
Articles from other publishers (74)
Thorsten Steinberg, Martin Philipp Dieterle, Imke Ramminger, Charlotte Klein, Julie Brossette, Ayman Husari & Pascal Tomakidi. (2023) On the Value of In Vitro Cell Systems for Mechanobiology from the Perspective of Yes-Associated Protein/Transcriptional Co-Activator with a PDZ-Binding Motif and Focal Adhesion Kinase and Their Involvement in Wound Healing, Cancer, Aging, and Senescence. International Journal of Molecular Sciences 24:16, pages 12677.
Crossref
Crossref
Mateusz Kciuk, Manzar Alam, Nemat Ali, Summya Rashid, Pola Głowacka, Rajamanikandan Sundaraj, Ismail Celik, Esam Bashir Yahya, Amit Dubey, Enfale Zerroug & Renata Kontek. (2023) Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications. Molecules 28:13, pages 5246.
Crossref
Crossref
Xu Zheng, Xing Li, Liangliang Tian, Bin Wu, Jiawen Yu, Changyuan Wang, Xiuli Sun, Xiaodong Ma, Lixue Chen & Yanxia Li. (2022) Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer. European Journal of Medicinal Chemistry 241, pages 114607.
Crossref
Crossref
Ana Carla Castro-Guijarro, Fiorella Vanderhoeven, Joselina Magali Mondaca, Analía Lourdes Redondo, Felipe Carlos Martin Zoppino, Juan Manuel Fernandez-Muñoz, Angel Matias Sanchez & Marina Inés Flamini. (2022) Combination Treatment of Retinoic Acid Plus Focal Adhesion Kinase Inhibitor Prevents Tumor Growth and Breast Cancer Cell Metastasis. Cells 11:19, pages 2988.
Crossref
Crossref
Ioanna Mourkioti, Andriani Angelopoulou, Konstantinos Belogiannis, Nefeli Lagopati, Spyridon Potamianos, Efthymios Kyrodimos, Vassilis Gorgoulis & Angelos Papaspyropoulos. (2022) Interplay of Developmental Hippo–Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells 11:15, pages 2449.
Crossref
Crossref
Anna‐Katharina Müller, Ulrike A. Köhler, Sébastien Trzebanski, Yaron Vinik, Harsha Mohan Raj, Jean‐Antoine Girault, Nir Ben‐Chetrit, Antonio Maraver, Steffen Jung & Sima Lev. (2022) Mouse Modeling Dissecting Macrophage–Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis. Advanced Science 9:9, pages 2105696.
Crossref
Crossref
Ping Liu, Yinghui Sun, Shuang Liu, Jing Niu, Xijie Liu & Qiaoyun Chu. (2022) SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells. Acta Biochimica et Biophysica Sinica 54:2, pages 252-260.
Crossref
Crossref
Patricia A. Quispe, Martin J. Lavecchia & Ignacio E. León. (2022) Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence. Drug Discovery Today 27:2, pages 664-674.
Crossref
Crossref
Muhamad Mustafa, Amer Ali Abd El-Hafeez, Dalia A Abdelhafeez, Dalia Abdelhamid, Yaser A Mostafa, Pradipta Ghosh, Alaa M Hayallah & Gamal El-Din A Abuo-Rahma. (2021) FAK inhibitors as promising anticancer targets: present and future directions. Future Medicinal Chemistry 13:18, pages 1559-1590.
Crossref
Crossref
Xiao-Jing Pang, Xiu-Juan Liu, Yuan Liu, Wen-Bo Liu, Yin-Ru Li, Guang-Xi Yu, Xin-Yi Tian, Yan-Bing Zhang, Jian Song, Cheng-Yun Jin & Sai-Yang Zhang. (2021) Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. Molecules 26:14, pages 4250.
Crossref
Crossref
Akshita Chauhan & Tabassum Khan. (2020) Focal adhesion kinase—An emerging viable target in cancer and development of focal adhesion kinase inhibitors. Chemical Biology & Drug Design 97:3, pages 774-794.
Crossref
Crossref
Kelly Coffey. (2021) Targeting the Hippo Pathway in Prostate Cancer: What’s New?. Cancers 13:4, pages 611.
Crossref
Crossref
Enrica Urciuoli & Barbara Peruzzi. (2020) Involvement of the FAK Network in Pathologies Related to Altered Mechanotransduction. International Journal of Molecular Sciences 21:24, pages 9426.
Crossref
Crossref
Yang Lu & Haiying Sun. (2020) Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). Journal of Medicinal Chemistry 63:23, pages 14382-14403.
Crossref
Crossref
Anthony Feral, Guillaume Laconde, Muriel Amblard & Nicolas Masurier. (2020) PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances. Advanced Therapeutics 3:11, pages 2000148.
Crossref
Crossref
Hongying Gao, Yue Wu, Yonghui Sun, Yiqing Yang, Guangbiao Zhou & Yu Rao. (2019) Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. ACS Medicinal Chemistry Letters 11:10, pages 1855-1862.
Crossref
Crossref
Yueheng Qi, Ye Li, Yu Fang, Bingchao Qiang, Hang Gao, Shuxia Wang & Huabei Zhang. (2020) Design, synthesis, and biological evaluation of F-18-labelled 2, 4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumour imaging agents. Bioorganic & Medicinal Chemistry Letters 30:19, pages 127452.
Crossref
Crossref
Yusuke Goto, Toshinori Ando, Hiroki Izumi, Xiaodong Feng, Nadia Arang, Mara Gilardi, Zhiyong Wang, Kazuyo Ando & J. Silvio Gutkind. (2020) Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK–YAP signaling axis. Oncogene 39:20, pages 4014-4027.
Crossref
Crossref
Jamie M. Aye, Laura L. Stafman, Adele P. Williams, Evan F. Garner, Jerry E. Stewart, Joshua C. Anderson, Smitha Mruthyunjayappa, Mary G. Waldrop, Caroline D. Goolsby, Hooper R. Markert, Colin Quinn, Raoud Marayati, Elizabeth Mroczek-Musulman, Christopher D. Willey, Karina J. Yoon, Kimberly F. Whelan & Elizabeth A. Beierle. (2019) The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor. Oncotarget 10:53, pages 5534-5548.
Crossref
Crossref
James M. Murphy, Kyuho Jeong, Yelitza A. R. Rodriguez, Jung-Hyun Kim, Eun-Young Erin Ahn & Ssang-Taek Steve Lim. (2019) FAK and Pyk2 activity promote TNF-α and IL-1β-mediated pro-inflammatory gene expression and vascular inflammation. Scientific Reports 9:1.
Crossref
Crossref
Shyam More, Emilie Vomhof‑Dekrey & Marc Basson. (2019) ZINC4085554 inhibits cancer cell adhesion by interfering with the interaction of Akt1 and FAK. Oncology Letters.
Crossref
Crossref
Asmaa E. Kassab & Rasha A. Hassan. (2018) Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition. Bioorganic Chemistry 80, pages 531-544.
Crossref
Crossref
Stefanie Tiede, Nathalie Meyer-Schaller, Ravi Kiran Reddy Kalathur, Robert Ivanek, Ernesta Fagiani, Philip Schmassmann, Patrick Stillhard, Simon Häfliger, Norbert Kraut, Norbert Schweifer, Irene C. Waizenegger, Ruben Bill & Gerhard Christofori. (2018) The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis 7:9.
Crossref
Crossref
Radhakrishnan Vishnubalaji, Muthurangan Manikandan, Mohamed Fahad, Rimi Hamam, Musaad Alfayez, Moustapha Kassem, Abdullah Aldahmash & Nehad M. Alajez. (2018) Molecular profiling of ALDH1+ colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget 9:17, pages 13551-13564.
Crossref
Crossref
Yu Fang, Dawei Wang, Xingyu Xu, Gila Dava, Jianping Liu, Xiang Li, Qianqian Xue, Huan Wang, Jiangshan Zhang & Huabei Zhang. (2018)
Preparation,
in vitro
and
in vivo
evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK)
. RSC Advances 8:19, pages 10333-10345.
Crossref
Crossref
Asma Begum, Theodore Ewachiw, Clinton Jung, Ally Huang, K. Jessica Norberg, Luigi Marchionni, Ross McMillan, Vesselin Penchev, N. V. Rajeshkumar, Anirban Maitra, Laura Wood, Chenguang Wang, Christopher Wolfgang, Ana DeJesus-Acosta, Daniel Laheru, Irina M. Shapiro, Mahesh Padval, Jonathan A. Pachter, David T. Weaver, Zeshaan A. Rasheed & William Matsui. (2017) The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLOS ONE 12:7, pages e0180181.
Crossref
Crossref
Masakazu Sato, Kei Kawana, Katsuyuki Adachi, Asaha Fujimoto, Mitsuyo Yoshida, Hiroe Nakamura, Haruka Nishida, Tomoko Inoue, Ayumi Taguchi, Juri Ogishima, Satoko Eguchi, Aki Yamashita, Kensuke Tomio, Osamu Wada-Hiraike, Katsutoshi Oda, Takeshi Nagamatsu, Yutaka Osuga & Tomoyuki Fujii. (2017) Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro. International Journal of Oncology 50:4, pages 1431-1438.
Crossref
Crossref
Yuyan Qian, Meiying Shao, Wenlin Zou, Linyan Wang, Ran Cheng & Tao Hu. (2017) Focal adhesion kinase maintains, but not increases the adhesion of dental pulp cells. Human Cell 30:2, pages 98-105.
Crossref
Crossref
Yu Fang, Dawei Wang, Xingyu Xu, Jianping Liu, Aiqin Wu, Xiang Li, Qianqian Xue, Huan Wang, Hang Wang & Huabei Zhang. (2017) Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor. European Journal of Medicinal Chemistry 127, pages 493-508.
Crossref
Crossref
Nadia Panera, Annalisa Crudele, Ilaria Romito, Daniela Gnani & Anna Alisi. (2017) Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. International Journal of Molecular Sciences 18:1, pages 99.
Crossref
Crossref
Israa Salem, Manal Alsalahi, Inna Chervoneva, Lucy D. Aburto, Sankar Addya, Gregory R. Ott, Bruce A. Ruggeri, Massimo Cristofanilli & Sandra V. Fernandez. (2016) The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. Breast Cancer Research 18:1.
Crossref
Crossref
Hannah E. Majeski & Jing Yang. (2016) The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer. Molecular Pharmacology 90:6, pages 744-754.
Crossref
Crossref
Bishoy M Faltas, Davide Prandi, Scott T Tagawa, Ana M Molina, David M Nanus, Cora Sternberg, Jonathan Rosenberg, Juan Miguel Mosquera, Brian Robinson, Olivier Elemento, Andrea Sboner, Himisha Beltran, Francesca Demichelis & Mark A Rubin. (2016) Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics 48:12, pages 1490-1499.
Crossref
Crossref
Julie Farand, Nicholas Mai, Jayaraman Chandrasekhar, Zachary E. Newby, Josh Van Veldhuizen, Jennifer Loyer-Drew, Chandrasekar Venkataramani, Juan Guerrero, Amy Kwok, Ning Li, Yelena Zherebina, Sibylle Wilbert, Jeff Zablocki, Gary Phillips, William J. Watkins, Robert Mourey & Gregory T. Notte. (2016) Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency. Bioorganic & Medicinal Chemistry Letters 26:24, pages 5926-5930.
Crossref
Crossref
Na Shang, Maribel Arteaga, Lennox Chitsike, Fang Wang, Navin Viswakarma, Peter Breslin & Wei Qiu. (2016) FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy. Scientific Reports 6:1.
Crossref
Crossref
Brittelle E. Kessler, Vibha Sharma, Qiong Zhou, Xia Jing, Laura A. Pike, Anna A. Kerege, Sharon B. Sams & Rebecca E. Schweppe. (2016) FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Molecular Cancer Research 14:9, pages 869-882.
Crossref
Crossref
Yu-Ling Tai, I-Rue Lai, Yu-Ju Peng, Shih-Torng Ding & Tang-Long Shen. (2016) Activation of focal adhesion kinase through an interaction with β4 integrin contributes to tumorigenicity of colon cancer. FEBS Letters 590:12, pages 1826-1837.
Crossref
Crossref
Toshio Shimizu, Kazuya Fukuoka, Masayuki Takeda, Tutomu Iwasa, Takeshi Yoshida, Joanna Horobin, Mitchell Keegan, Lou Vaickus, Ajit Chavan, Mahesh Padval & Kazuhiko Nakagawa. (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 77:5, pages 997-1003.
Crossref
Crossref
Chao Chen, Ruixia Li, Robert S. Ross & Ana Maria Manso. (2016) Integrins and integrin-related proteins in cardiac fibrosis. Journal of Molecular and Cellular Cardiology 93, pages 162-174.
Crossref
Crossref
Grant A. Howe, Bin Xiao, Huijun Zhao, Khalid N. Al-Zahrani, Mohamed S. Hasim, James Villeneuve, Harmanjatinder S. Sekhon, Glenwood D. Goss, Luc A. Sabourin, Jim Dimitroulakos & Christina L. Addison. (2016) Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. PLOS ONE 11:3, pages e0150567.
Crossref
Crossref
John Wilton, Elena Kurenova, Laura Pitzonka, Allison Gaudy, Leslie Curtin, Sandra Sexton, William Cance & Gerald Fetterly. (2014) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. European Journal of Drug Metabolism and Pharmacokinetics 41:1, pages 55-67.
Crossref
Crossref
Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni R. A. Razak, Jeffrey R. Infante, Shuchi S. Pandya, Philippe L. Bedard, Kristen J. Pierce, Brett Houk, W. Gregory Roberts, S. Martin Shreeve & Geoffrey I. Shapiro. (2015) A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs 33:5, pages 1100-1107.
Crossref
Crossref
Claire Béraud, Valérian Dormoy, Sabrina Danilin, Véronique Lindner, Audrey Béthry, Mazène Hochane, Catherine Coquard, Mariette Barthelmebs, Didier Jacqmin, Hervé Lang & Thierry Massfelder. (2015) Targeting FAK scaffold functions inhibits human renal cell carcinoma growth. International Journal of Cancer 137:7, pages 1549-1559.
Crossref
Crossref
Philip J. Webber, Chanhee Park, Min Qui, Suresh S. Ramalingam, Fadlo R. Khuri, Haian Fu & Yuhong Du. (2015) Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. Oncoscience 2:9, pages 765-776.
Crossref
Crossref
Amrita Datta, Nobel Bhasin, Hogyoung Kim, Manish Ranjan, Barbara Rider, Zakaria Y. Abd Elmageed, Debasis Mondal, Krishna C. Agrawal & Asim B. Abdel-Mageed. (2015) Selective targeting of FAK–Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells. Cancer Letters 362:1, pages 25-35.
Crossref
Crossref
Byungdo B. Han, Suyang Li, Meng Tong, Andrew S. Holpuch, Richard Spinney, Daren Wang, Michael B. Border, Zhongfa Liu, Sachin Sarode, Ping Pei, Steven P. Schwendeman & Susan R. Mallery. (2015) Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes. Fenretinide's Chemopreventive Mechanisms Include ECM Interactions. Cancer Prevention Research 8:5, pages 419-430.
Crossref
Crossref
Brian Y. Lee, Paul Timpson, Lisa G. Horvath & Roger J. Daly. (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacology & Therapeutics 146, pages 132-149.
Crossref
Crossref
Na Shang, Maribel Arteaga, Ali Zaidi, Jimmy Stauffer, Scott J. Cotler, Nancy J. Zeleznik‐Le, Jiwang Zhang & Wei Qiu. (2014) FAK Is required for c‐Met/β‐catenin‐driven hepatocarcinogenesis. Hepatology 61:1, pages 214-226.
Crossref
Crossref
Miriam A Shelef, David A Bennin, Nihad Yasmin, Thomas F Warner, Thomas Ludwig, Hilary E Beggs & Anna Huttenlocher. (2014) Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis. Arthritis Research & Therapy 16:5.
Crossref
Crossref
Florian J. Sulzmaier, Christine Jean & David D. Schlaepfer. (2014) FAK in cancer: mechanistic findings and clinical applications. Nature Reviews Cancer 14:9, pages 598-610.
Crossref
Crossref
Guillermina M. Goñi, Carolina EpifanoJasminka Boskovic, Marta Camacho-Artacho, Jing ZhouAgnieszka BronowskaM. Teresa MartínMichael J. Eck, Leonor KremerFrauke GräterFrancesco Luigi Gervasio, Mirna Perez-MorenoDaniel Lietha. (2014) Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes. Proceedings of the National Academy of Sciences 111:31.
Crossref
Crossref
Yuen Yee Ho, David Lagares, Andrew M. Tager & Mohit Kapoor. (2014) Fibrosis—a lethal component of systemic sclerosis. Nature Reviews Rheumatology 10:7, pages 390-402.
Crossref
Crossref
Nina R. Shah, Isabelle Tancioni, Kristy K. Ward, Christine Lawson, Xiao Lei Chen, Christine Jean, Florian J. Sulzmaier, Sean Uryu, Nichol L.G. Miller, Denise C. Connolly & David D. Schlaepfer. (2014) Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecologic Oncology 134:1, pages 104-111.
Crossref
Crossref
Jianliang Zhang & Steven N. Hochwald. (2014) The role of FAK in tumor metabolism and therapy. Pharmacology & Therapeutics 142:2, pages 154-163.
Crossref
Crossref
Heejei Yoon, Yoon-La Choi, Ji-Young Song, Ingu Do, So Young Kang, Young-Hyeh Ko, Sangyong Song & Byoung-Gie Kim. (2014) Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines. PLoS ONE 9:2, pages e88587.
Crossref
Crossref
Brian Y. Lee, Falko Hochgräfe, Hui-Ming Lin, Lesley Castillo, Jianmin Wu, Mark J. Raftery, S. Martin Shreeve, Lisa G. Horvath & Roger J. Daly. (2014) Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics 13:1, pages 190-201.
Crossref
Crossref
Andrew J. Wiemer, Sarah A. Wernimont, Thai-duong Cung, David A. Bennin, Hilary E. Beggs & Anna Huttenlocher. (2013) The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation. Biochemical Pharmacology 86:6, pages 770-781.
Crossref
Crossref
Erik H. J. Danen. (2013) Integrin Signaling as a Cancer Drug Target. ISRN Cell Biology 2013, pages 1-14.
Crossref
Crossref
Marine Barbelanne, Jenny Song, Mustafa Ahmadzai & William Y. Tsang. (2013) Pathogenic NPHP5 mutations impair protein interaction with Cep290, a prerequisite for ciliogenesis. Human Molecular Genetics 22:12, pages 2482-2494.
Crossref
Crossref
Stellar BooLina Dagnino. (2013) Integrins as Modulators of Transforming Growth Factor Beta Signaling in Dermal Fibroblasts During Skin Regeneration After Injury. Advances in Wound Care 2:5, pages 238-246.
Crossref
Crossref
Andrew Leask. (2013) Focal Adhesion Kinase: A Key Mediator of Transforming Growth Factor Beta Signaling in Fibroblasts. Advances in Wound Care 2:5, pages 247-249.
Crossref
Crossref
Kristy K. Ward, Isabelle Tancioni, Christine Lawson, Nichol L. G. Miller, Christine Jean, Xiao Lei Chen, Sean Uryu, Josephine Kim, David Tarin, Dwayne G. Stupack, Steven C. Plaxe & David D. Schlaepfer. (2012) Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clinical & Experimental Metastasis 30:5, pages 579-594.
Crossref
Crossref
Colleen S. Curran & Patricia J. Keely. (2013) Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition. Matrix Biology 32:2, pages 95-105.
Crossref
Crossref
David Lagares & Mohit Kapoor. (2012) Targeting Focal Adhesion Kinase in Fibrotic Diseases. BioDrugs 27:1, pages 15-23.
Crossref
Crossref
Wenjing Zhang, Bo Tang, Qilai Huang & Zichun Hua. (2012) Galangin inhibits tumor growth and metastasis of B16F10 melanoma. Journal of Cellular Biochemistry 114:1, pages 152-161.
Crossref
Crossref
Lisa SavilleChrysanthe SpaisJennifer L. MasonMark S. AlbomSeetha MurthySheryl L. MeyerMark A. AtorThelma S. AngelesJean Husten. (2012) Time-Resolved Fluorescence Resonance Energy Transfer as a Versatile Tool in the Development of Homogeneous Cellular Kinase Assays. ASSAY and Drug Development Technologies 10:6, pages 551-557.
Crossref
Crossref
Matthew P. Ablett, Jagdeep K. Singh & Robert B. Clarke. (2012) Stem cells in breast tumours: Are they ready for the clinic?. European Journal of Cancer 48:14, pages 2104-2116.
Crossref
Crossref
Ssang-Taek Lim, Nichol L.G. Miller, Xiao Lei Chen, Isabelle Tancioni, Colin T. Walsh, Christine Lawson, Sean Uryu, Sara M. Weis, David A. Cheresh & David D. Schlaepfer. (2012) Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. Journal of Cell Biology 197:7, pages 907-919.
Crossref
Crossref
V. M. Golubovskaya, S. Figel, B. T. Ho, C. P. Johnson, M. Yemma, G. Huang, M. Zheng, C. Nyberg, A. Magis, D. A. Ostrov, I. H. Gelman & W. G. Cance. (2012) A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 33:5, pages 1004-1013.
Crossref
Crossref
Tanguy Lechertier & Kairbaan Hodivala-Dilke. (2012) Focal adhesion kinase and tumour angiogenesis. The Journal of Pathology 226:2, pages 404-412.
Crossref
Crossref
Miguel A. Cabrita, Laura M. Jones, Jennifer L. Quizi, Luc A. Sabourin, Bruce C. McKay & Christina L. Addison. (2011) Focal adhesion kinase inhibitors are potent anti‐angiogenic agents. Molecular Oncology 5:6, pages 517-526.
Crossref
Crossref
Karen E. Eberle, Hope A. Sansing, Peter Szaniszlo, Vicente A. Resto & Allison L. Berrier. (2011) Carcinoma Matrix Controls Resistance to Cisplatin through Talin Regulation of NF-kB. PLoS ONE 6:6, pages e21496.
Crossref
Crossref
J Bunek, P Kamarajan & YL Kapila. (2010) Anoikis mediators in oral squamous cell carcinoma. Oral Diseases 17:4, pages 355-361.
Crossref
Crossref
Carol Box, Susanne J. Rogers, Marta Mendiola & Suzanne A. Eccles. (2010) Tumour-microenvironmental interactions: paths to progression and targets for treatment. Seminars in Cancer Biology 20:3, pages 128-138.
Crossref
Crossref